Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder
Publication: American Journal of Psychiatry
Abstract
Objective:
Early evidence suggests that ketamine may be an effective treatment to sustain abstinence from alcohol. The authors investigated the safety and efficacy of ketamine compared with placebo in increasing abstinence in patients with alcohol use disorder. An additional aim was to pilot ketamine combined with mindfulness-based relapse prevention therapy compared with ketamine and alcohol education as a therapy control.
Methods:
In a double-blind placebo-controlled phase 2 clinical trial, 96 patients with severe alcohol use disorder were randomly assigned to one of four conditions: 1) three weekly ketamine infusions (0.8 mg/kg i.v. over 40 minutes) plus psychological therapy, 2) three saline infusions plus psychological therapy, 3) three ketamine infusions plus alcohol education, or 4) three saline infusions plus alcohol education. The primary outcomes were self-reported percentage of days abstinent and confirmed alcohol relapse at 6-month follow-up.
Results:
Ninety-six participants (35 women; mean age, 44.07 years [SD=10.59]) were included in the intention-to-treat analysis. The treatment was well tolerated, and no serious adverse events were associated with the study drug. Although confidence intervals were wide, consistent with a proof-of-concept study, there were a significantly greater number of days abstinent from alcohol in the ketamine group compared with the placebo group at 6-month follow-up (mean difference=10.1%, 95% CI=1.1, 19.0), with the greatest reduction in the ketamine plus therapy group compared with the saline plus education group (15.9%, 95% CI=3.8, 28.1). There was no significant difference in relapse rate between the ketamine and placebo groups.
Conclusions:
This study demonstrated that treatment with three infusions of ketamine was well tolerated in patients with alcohol use disorder and was associated with more days of abstinence from alcohol at 6-month follow-up. The findings suggest a possible beneficial effect of adding psychological therapy alongside ketamine treatment.
Harmful use of alcohol causes more than 5% of the disease burden worldwide (1), but a great proportion of individuals with alcohol use disorder (AUD) do not respond to currently available pharmacological and behavioral treatments, with more than 70% of those entering treatment relapsing within 1 year (2). The N-methyl-d-aspartate receptor antagonist ketamine is a promising candidate therapy in AUD for several reasons. First, substantial evidence supports the antidepressant properties of subanesthetic doses of ketamine (3), leading to the recent U.S. Food and Drug Administration and European Medicines Agency approval of esketamine, an enantiomer of ketamine, for use in treatment-resistant depression. Depressive symptoms are common in individuals entering treatment for AUD, and the likelihood of alcohol relapse is elevated in patients with such symptoms (4, 5). Ketamine may support alcohol abstinence by temporarily alleviating depressive symptoms during the high-risk relapse period in the weeks after detoxification.
Second, ketamine might aid alcohol abstinence by providing a window during which psychological therapies can be more effective. Evidence from preclinical studies suggests that ketamine increases synaptogenesis and neurogenesis, known to be disrupted with addiction (6, 7). Learning and planning are impaired in patients with AUD, and these deficits likely underpin the limited effectiveness of therapy in patients suffering from AUD (8, 9). Ketamine may provide a temporary boost to synaptogenesis and neurogenesis, which may allow psychological therapies and new strategies for managing addiction to embed more readily (10). There is little empirical evidence on the effectiveness of psychological therapy provided in conjunction with ketamine treatment, but one study suggested that 10 weeks of cognitive-behavioral therapy (CBT) alongside ketamine infusions may prolong ketamine-induced symptom reduction in treatment-resistant depression (11). The subjective experiences that accompany ketamine infusions may provide a new perspective that may be helpful in psychological therapy. Ketamine induces a dose-dependent sense of dissociation and disembodiment that has been described as facilitating an “observer state” similar to that described in mindfulness, which may be helpful for allowing patients to consider thoughts and emotions from a more removed perspective (12).
Third, several studies have directly investigated the effect of ketamine on patients with problematic alcohol use. An early, nonrandomized study (13) found that three subanesthetic doses of ketamine (2.5 mg/kg i.m.) adjunctive to psychodynamic psychotherapy led to a 1-year abstinence rate (at outpatient follow-up) of 66% in a group of inpatients with AUD after detoxification, compared with 24% in a conventional-treatment control group. The positive impact of ketamine on AUD was corroborated recently (12) in a study of 40 outpatients randomized to a single infusion of either ketamine (0.71 mg/kg i.v.) or the active placebo midazolam alongside motivational enhancement therapy in both conditions. At 21 days, 47% of the ketamine group reported using alcohol, compared with 59% of the midazolam group. In a study of individuals with hazardous drinking patterns (14), one intravenous ketamine infusion combined with a memory reactivation protocol, but no therapy intervention, was associated with reduced alcohol use at 6 months.
Given the antidepressant properties of ketamine, very early evidence that it might aid psychological therapy, and a few studies showing initial benefits of ketamine as a treatment for AUD, in the present study we set out to investigate the safety and feasibility of ketamine infusions compared with saline infusions in increasing abstinence in patients with alcohol use disorder. In this study, three ketamine infusions were administered weekly, as this has been shown to be effective in earlier research (13). We furthermore aimed to pilot ketamine combined with mindfulness-based relapse prevention therapy (henceforth “therapy”) compared with ketamine plus alcohol education (as a therapy control). This type of psychological therapy was chosen because it has been shown to be effective, and the ketamine experience can be considered to potentially promote engagement in mindfulness practice by giving experiential insights. Thus, in this phase 2 clinical trial, we compared four treatment conditions: 1) ketamine (active) and therapy (active), 2) ketamine (active) and alcohol education (control), 3) saline (control) and therapy (active), and 4) saline (control) and alcohol education (control). We hypothesized that ketamine plus therapy (active plus active) would be most effective in sustaining abstinence and that the lowest abstinence rates would be in the placebo plus education group (control plus control).
METHODS
Participants
Participants were recruited from the community through social media and newspaper and radio advertisements as well as from primary care and secondary care drug and alcohol services.
All participants had to achieve initial abstinence at randomization, meaning that they had to be abstinent for at least 24 hours and have a reading of 0.0 on a breath alcohol test at the baseline visit. This allowed us to investigate the impact of ketamine on prolonging abstinence. Participants were also required to have the goal of abstinence for at least the 6 months of the trial. Current level of alcohol use was assessed during an initial telephone screening, and alcohol-abstinent individuals were immediately invited to a screening visit. Individuals who were drinking at levels that meant they could safely cut down to abstinence within 4 weeks were asked to do so and then scheduled for a screening visit. Alternatively, potential participants were encouraged to undergo a supervised detoxification in primary care or through their current treatment provider, and once initial abstinence had been achieved, they were invited for a screening visit. At the screening visit, after written informed consent was obtained, eligibility was determined by the study physician, based on the patient’s medical history, physical examination, mental health assessments, blood and urine analysis, and a breath alcohol test. At the end of the study, participants were remunerated to compensate them for the time spent in the study, at a level correspondent to the national living wage.
Eligible participants had to be 18–65 years old, meet DSM-5 criteria for moderate to severe AUD or DSM-IV criteria for AUD, have a good command of the English language, be currently abstinent from alcohol, and have a negative urine screen for all drugs apart from cannabis and benzodiazepines; these exceptions were based on the long half-life of these drugs and the fact that cannabis is comorbid with AUD and benzodiazepines are commonly prescribed in AUD for sleeping problems. Current or past dependence on either of these drugs was an exclusion criterion.
Key exclusion criteria were uncontrolled hypertension (systolic blood pressure ≥140 mmHg and diastolic blood pressure >90 mmHg), the use of antihypertensives or antidepressants, current suicidal ideation, a diagnosis of any current or past psychiatric disorder (except for depression, anxiety, AUD, or alcohol dependence) or of substance dependence (except for AUD) or ever seeking professional help for dependence on an illicit substance. Study applicants who had more than 10 previous inpatient alcohol detoxifications or a history of harmful ketamine use were also excluded (a full list of the inclusion and exclusion criteria is provided in the online supplement).
All procedures and patient visits took place at either the National Institute for Health Research (NIHR) Exeter Clinical Research Facility or the NIHR University College London Hospitals Clinical Research Facility. The trial was registered at ClinicalTrials.gov (NCT02649231) and EudraCT (2015-000222-11) (15). Ethical approval was granted by the South West–Central Bristol Research Ethics Committee (reference number 15/SW/0312) and the Medicines and Healthcare Products Regulatory Agency. All analyses were preplanned and registered at EudraCT and ClinicalTrials.gov unless indicated otherwise.
Study Design
In this double-blind phase 2 clinical trial, recently detoxified adults with AUD were randomly assigned to one of four treatment arms: 1) ketamine (active) and therapy (active), 2) ketamine (active) and alcohol education (control), 3) saline (control) and therapy (active) and, 4) saline (control) and alcohol education (control). Participants were invited to attend 10 study visits (Figure 1). Self-reported drinking events were recorded at every visit using the timeline followback method. Participants were provided with an alcohol diary to record their alcohol use between visits 8 and 9 and between visits 9 and 10. A Secure Continuous Remote Alcohol Monitor (SCRAM; Alcohol Monitoring Systems, Inc.) bracelet for continuous alcohol monitoring (every 30 minutes) was attached before randomization at visit 1 or 2 and removed at visit 8 (end of treatment), to corroborate self-reported alcohol timeline followback outcomes.
FIGURE 1. Schematic of the trial design in a study of ketamine and psychological therapy in the treatment of alcohol use disordera
a Visits highlighted in red were repeated three times, 1–3 weeks apart. Visits 3, 5, and 7 (therapy and education sessions) occurred about 24 hours after infusion visits 2, 4, and 6.
Randomization and Masking
Participants were randomized in a 1:1:1:1 ratio using a block design stratified by treatment site to one of the four treatment arms at the beginning of visit 2. All staff except for pharmacy staff, who had no contact with participants, were blinded to drug treatment allocation, and all except the therapists were blind to the allocation to therapy or education.
Therapy and Alcohol Education Control
At visit 2 and the subsequent six visits, participants received either manualized therapy or alcohol education as a placebo control for therapy. Both were administered by trained psychologists, with all therapists delivering both types of treatment. The sessions were timed so that the infusion was always preceded by a therapy or alcohol education session and followed by another therapy or alcohol education session about 24 hours later.
Therapy.
The aim of the seven therapy sessions based on manualized mindfulness-based relapse prevention was to support the participants in developing an enjoyable and meaningful life without alcohol (16). Each session was designed to last 1.5 hours and contained one topic related to each of the two overarching themes of the therapy: relapse prevention and the promotion of well-being. In between these two main themes, a different relaxation or mindfulness exercise was introduced in each session. The sessions covered a range of relapse prevention techniques, including dealing with high-risk situations, activity scheduling, and problem solving, alongside dealing with thinking biases (CBT-based), mindfulness practice, and techniques such as urge surfing. Patients were also required to reflect on resources needed for a meaningful life without alcohol. Between sessions, patients used journals to record and reflect on their experiences and completed a number of exercises, alongside mindfulness practice. All therapy sessions were recorded, and an independent consultant clinical psychologist reviewed recordings on a weekly or biweekly basis to check adherence to the treatment protocol. The therapy manual was incorporated into a step-by-step scripted “guidebook” for the participant and therapist that was designed to be prescriptive, to facilitate adherence to the therapy protocol.
Alcohol education.
The seven alcohol education sessions were also designed to last 1.5 hours so that interpersonal interaction time matched the psychological therapy, to act as a control for the therapy condition. During these sessions, the focus was on educational topics, including the driving forces of addiction, the biological effects of alcohol, and ways to improve healthy living and nutrition. In contrast to the psychological therapy, these sessions had no formal psychological components relating to personal relapse prevention strategies, mindfulness, or the promotion of personal well-being.
Drug Administration
The infusions were administered at visits 2, 4, and 6. These visits were spaced apart a minimum of 1 week and a maximum of 3 weeks and lasted for 40 minutes. Ketamine (0.8 mg/kg) and placebo (0.9% saline) of the same volume were administered as intravenous infusions. The dose was higher than in depression studies, based on findings of possible cross-tolerance to ketamine in people with AUD (17), and it roughly equates to what was suggested to be the lowest effective intramuscular dose (1.2 mg/kg) in alcohol-dependent patients (E. Krupitsky, personal communication, 2012). The intravenous route was used because it is considered the best method to control ketamine blood levels and is associated with fewer adverse effects, such as nausea, than intramuscular administration. Intravenous administration has by now been established as the conventional method for administering ketamine for therapeutic purposes. Saline was used instead of an active placebo because upon starting this study, it was the first in this patient group since the early work in Russia (13), and we were concerned that an active placebo (e.g., a benzodiazepine) might have unintended therapeutic consequences (18).
Before each infusion, patients were prepared in terms of potential ketamine experiences by the therapist (see reference 19 for further details) and how they might reflect on the previous therapy session during the drug experience, including directions to use the relaxation or mindfulness techniques learned prior to the infusion during the experience. Patients were asked to bring to mind, where possible, their intention for a life without alcohol. A therapist was present and available throughout the infusion to provide reassurance if the patient required it.
The infusion was administered by an anesthetist through a cannula in a vein in the antecubital fossa. Blood pressure, heart rate, and blood oxygen saturation levels were measured. A psychologist and a nurse were present during the infusion. During the infusion, participants listened to instrumental music through headphones in a single-bed hospital room to facilitate relaxation and minimize distraction from external stimuli. Participants rated potential side effects at −20 minutes, 0 minutes (start of infusion), 20 minutes (midinfusion), 40 minutes (end of infusion), and 60, 80, 100, and 120 minutes after the infusion. These were assessed by a research nurse or psychologist.
Primary Outcomes
The co–primary outcomes were self-reported percentage days abstinent and confirmed alcohol relapse at 6 months after first infusion, both measured using the Alcohol Timeline Followback self-report questionnaire. Confirmed relapse for this study was defined as one or more days of heavy alcohol use; heavy use was defined as >64.8 g of pure alcohol for men (8.1 standard U.K. units) and >52.0 g for women (6.5 standard U.K. units) per day (20). Abstinence was defined as no alcohol consumption.
Secondary Outcomes
Alcohol-related secondary outcomes were self-reported relapse and percentage days abstinent at 3 months. Other secondary outcomes included depressive symptoms, measured using the Beck Depression Inventory (BDI) (21) and the Hamilton Depression Rating Scale (HAM-D) (22); general health, measured by the 12-item Short Form Survey (SF-12) (23); psychotomimetic experiences (assessed before drug administration and included to index any protracted psychosis-like effects of ketamine and not as an indicator of acute effects), measured by the Psychotomimetic States Inventory (24); level of cigarette dependence, measured by the Fagerström Test for Nicotine Dependence (25); alcohol craving, measured by the Alcohol Craving Questionnaire (26); and SCRAM bracelet alcohol readings. The assessment time points for each measure as well as for other measures not presented here are listed in the online supplement.
Subjective Drug Effects
Other safety measures included acute subjective effects of ketamine assessed by the researcher through a visual analogue scale of common ketamine effects, vital signs, alcohol breath monitoring, and laboratory tests of liver function and ketamine as well as urine screens for pregnancy and drug use (27).
Blood Sample Analysis
Ketamine blood concentration was measured at each postrandomization visit and twice on infusion visits: shortly before and 2 hours after infusion.
Statistical Analysis
The main analytic method for all analyses was intention-to-treat (participants were analyzed according to their treatment allocation) and we used observed data only. All inferential analyses (for both primary and secondary outcomes) included adjustment for treatment site. For the primary outcomes, further sensitivity analyses were performed, including imputation of missing data and participants who received the full treatment. The study was not powered to assess an interaction between the drug and the therapy condition.
Self-reported alcohol relapse status and percentage days abstinent from randomization to 6-month follow-up were reported descriptively by treatment arm. Only participants with a minimum of 159 days of completed drinking self-report data were included in the main intention-to-treat analysis of alcohol relapse status, as this was the shortest duration of time before any participant completed the 6-month follow-up (23–25 weeks) in the study. Reporting time was capped at 180 days, but further sensitivity analyses were conducted with imputed data (multiple imputation method) and a per protocol analysis of only participants who received the full treatment. Logistic regression modeling was used to compare the ketamine group with the placebo group (combined across therapy and alcohol education). Additional models compared ketamine plus therapy and ketamine plus education, and ketamine plus therapy and placebo plus alcohol education. Self-reported percentage days abstinent at 3 months and longest abstinent spell within 3 months were also reported descriptively and analyzed using linear regression modeling, with the only sensitivity analysis being adjustment for baseline alcohol use.
Other secondary outcomes were reported descriptively at baseline, 3 months, and 6 months. Inferential analyses using linear regression with adjustment for site and baseline scores were used to compare the combined ketamine group and the combined placebo group at 3 months and 6 months. Repeated-measures analyses using hierarchical linear modeling with a random effect on participant were used to investigate the effects of ketamine compared with placebo for questionnaire outcomes across baseline, 12 days, 3 months, and 6 months, including all participants with data for at least one of these time points. Analyses for the Fagerström Test for Nicotine Dependence included only participants who were smokers at baseline.
For continuous data, effect sizes were calculated as standardized mean differences with associated 95% confidence intervals. If confidence intervals cross zero, this can be interpreted as a nonsignificant effect (alpha=0.05). The size of the value indicates the magnitude of the difference (28). For dichotomous data, odds ratios were calculated, which can be interpreted as percentage reduction if negative, and percentage increase if positive. If confidence intervals do not include 1, then this can be interpreted as a significant difference (alpha=0.05).
An exploratory analysis was conducted that was not in the original statistical analysis plan: The interaction between the ketamine and therapy conditions on percentage days abstinent at 3 and 6 months was tested using logistic regression modeling in the intention-to-treat population.
All analyses were performed using Stata, version 16. The statistician was blind to treatment group for the analyses of the primary outcomes and alcohol-related secondary outcomes.
RESULTS
Participant Characteristics
The participants’ demographic and clinical characteristics are summarized in Table 1.
| Characteristic | Ketamine + PT (N=24) | Ketamine + PE (N=24) | Placebo + PT (N=23) | Placebo + PE (N=25) | Total | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| Age (years) | 45.2 | 8.7 | 40.5 | 11.1 | 47.0 | 11.8 | 43.7 | 10.2 | 44.1 | 10.6 |
| N | % | N | % | N | % | N | % | N | % | |
| Male | 14 | 58 | 17 | 71 | 15 | 65 | 15 | 60 | 61 | 64 |
| Site | ||||||||||
| Exeter | 12 | 50 | 11 | 46 | 11 | 48 | 12 | 48 | 46 | 48 |
| London | 12 | 50 | 13 | 54 | 12 | 52 | 13 | 52 | 50 | 52 |
| History of depression | 14 | 58 | 10 | 42 | 9 | 39 | 7 | 28 | 40 | 42 |
| History of anxiety | 13 | 54 | 11 | 46 | 12 | 8 | 32 | 44 | 46 | |
| Prerandomization psychedelic drug use | ||||||||||
| Ever used ketamine | 7 | 29 | 4 | 17 | 5 | 22 | 10 | 40 | 26 | 27 |
| Ever used psilocybin | 10 | 42 | 12 | 50 | 14 | 60 | 11 | 44 | 47 | 49 |
| Ever used LSD | 10 | 42 | 7 | 29 | 11 | 48 | 14 | 56 | 42 | 44 |
| Number of infusions | ||||||||||
| 3 | 18 | 75 | 20 | 83 | 20 | 87 | 23 | 92 | 81 | 84 |
| 2 | 2 | 8 | 0 | 0 | 1 | 4 | 0 | 0 | 3 | 3 |
| 1 | 3 | 13 | 3 | 13 | 2 | 9 | 2 | 8 | 10 | 10 |
| 0 | 1 | 4 | 1 | 4 | 0 | 0 | 0 | 0 | 2 | 2 |
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | |
| Smoking (pack-years) | 11.4 | 15.5 | 7.0 | 10.9 | 13.1 | 20.5 | 13.0 | 15.6 | 11.1 | 15.9 |
| Alcohol consumption at randomization following reduction for abstinence (units per week) | 1.7 | 2.6 | 1.5 | 4.0 | 1.9 | 2.5 | 1.6 | 2.4 | 1.7 | 2.9 |
| Alcohol consumption at screening (units per week) | 32.0 | 34.0 | 44.0 | 42.5 | 26.0 | 24.0 | 34.9 | 33.9 | 34.7 | 34.3 |
| Number of DSM-5 criteria endorsed | 7.4 | 2.2 | 7.8 | 1.6 | 7.1 | 2.4 | 6.9 | 2.2 | 7.3 | 2.1 |
| Days since last drink at screening | 7.8 | 9.8 | 10.0 | 22.5 | 7.04 | 8.8 | 9.9 | 10.4 | 8.6 | 13.7 |
| Heaviest regular alcohol use (units per week) | 129.8 | 46.2 | 121.3 | 44.5 | 137.8 | 83.1 | 124.8 | 95.2 | 128.4 | 70.8 |
a
PE=psychoeducation; PT=psychotherapy.
The first patient was recruited in September 2016, and the last in July 2019. A total of 166 applicants attended a screening visit, of whom 96 met the eligibility criteria and were randomized to one of the four treatment arms (35 women; mean age, 44.07 years [SD=10.59]) (Figure 2). Most participants (95%) were recruited from the community through social media and newspaper and radio advertisements, and the remainder were recruited from primary care and secondary care drug and alcohol services. The treatment groups were similar in demographic and baseline clinical characteristics. Length of ketamine treatment (from randomization to visit 6) averaged 17.1 days (SD=4.7, range=12–35; N=81). Length of completed participation in the trial (from randomization to visit 10) averaged 190 days (SD=31, range=163–369; N=81). Forty-five percent of participants had a lifetime diagnosis of an anxiety disorder, and 40% a lifetime diagnosis of depression.
FIGURE 2. Distribution of participants by treatment arm in a study of ketamine and psychological therapy in the treatment of alcohol use disordera
a SCRAM=Secure Continuous Remote Alcohol Monitor; four participants discontinued because they were unable to tolerate wearing the SCRAM bracelet.
Ten participants reported having received inpatient detoxification at least once. On average, participants met 7.3 DSM-5 criteria for AUD (SD=2.1), and this was relatively evenly distributed across treatment groups. At screening, participants reported drinking an average of 34.5 U.K. standard units per week (SD=34.4) and 8.2 quit attempts (SD=16.3). At randomization, average alcohol use had been reduced to 1.7 U.K. standard units per week (SD=2.9) (see Table 1). Drug experimentation was common in this sample, as would be expected among a group with severe AUD, and while a comorbid substance use disorder was an exclusion criterion in the trial, 26% of participants had tried ketamine (up to 10 times previously), 49% had tried psilocybin (“magic mushrooms”), and 44% had tried LSD, although none were regular users.
Primary Outcomes
Based on the intention-to-treat analysis, there was a significantly greater percentage of days abstinent at 6-month follow-up in the ketamine compared with the placebo group, pooled across the therapy conditions (mean difference=10.1, 95% CI=1.1, 19.0) (Figure 3; see also Table S1 in the online supplement). Similar results were observed across sensitivity analyses, one including only participants who completed all treatment visits and one with missing data imputed (see the sensitivity analysis tables in the online supplement). No significant difference was found for relapse (recurrent heavy use) within 6 months (Table 2).
FIGURE 3. Percentage days abstinent across the four treatment conditions in a study of ketamine and psychological therapy in the treatment of alcohol use disordera
a The ketamine plus therapy group shows the greatest percentage days abstinent and the placebo plus psychoeducation group the lowest. Confidence intervals are not overlapping for these two most extreme groups at 12 weeks and 24 weeks. Number of participants at week 3: ketamine plus therapy, N=22; ketamine plus psychoeducation, N=23; placebo plus therapy, N=23; placebo plus psychoeducation, N=25. Number of participants at weeks 12 and 24: ketamine plus therapy, N=21; ketamine plus psychoeducation, N=22; placebo plus therapy, N=22; placebo plus psychoeducation, N=24.
| Outcome | Ketamine + PT (N=24) | Ketamine + PE (N=24) | Placebo + PT (N=23) | Placebo + PE (N=25) | Ketamine Versus Placebo | Ketamine + PT vs. Ketamine + PE | Ketamine + PT vs. Placebo + PE | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/N | % | n/N | % | n/N | % | n/N | % | Odds ratiob | 95% CI | Odds ratiob | 95% CI | Odds ratiob | 95% CI | |
| Confirmed alcohol relapse (maximum, 180 days) | ||||||||||||||
| 3 monthsc | 12/21 | 57 | 13/22 | 59 | 13/21 | 62 | 17/24 | 71 | ||||||
| 6 monthsd | 13/21 | 62 | 15/22 | 68 | 14/21 | 67 | 18/23 | 78 | 0.70 | 0.28, 1.75 | 0.75 | 0.21, 2.65 | 0.46 | 0.12, 1.74 |
| Confirmed alcohol relapsed,e (maximum, 180 days) | ||||||||||||||
| 6 months | 0.80 | 0.31, 2.10 | 0.53 | 0.12, 2.34 | 0.46 | 0.11, 1.84 | ||||||||
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean difff | 95% CI | |||||
| BDI score | ||||||||||||||
| Baseline | 9.5 | 7.3 | 8.3 | 7.8 | 9.7 | 9.2 | 8.2 | 6.9 | ||||||
| 3 months | 3.9 | 4.7 | 3.2 | 4.6 | 7.0 | 6.5 | 5.2 | 6.2 | –2.6 | –4.9, –0.4 | ||||
| 6 months | 5.9 | 8.1 | 5.5 | 6.3 | 8.2 | 8.0 | 5.0 | 4.7 | –1.1 | –3.7, 1.6 | ||||
| HAM-D score | ||||||||||||||
| Baseline | 3.9 | 3.9 | 3.1 | 2.5 | 5.1 | 4.7 | 3.3 | 3.8 | ||||||
| 3 months | 2.1 | 2.6 | 2.9 | 3.4 | 4.6 | 3.7 | 2.9 | 3.6 | –1.3 | –2.6, 0.1 | ||||
| 6 months | 4.1 | 5.3 | 4.7 | 5.7 | 5.1 | 4.3 | 2.9 | 3.5 | 0.3 | –1.7, 2.3 | ||||
a
BDI=Beck Depression Inventory; HAM-D=Hamilton Depression Rating Scale; mean diff=mean difference; PE=psychoeducation; PT=psychotherapy.
b
Adjusted for site.
c
Including only participants with confirmed relapse status; relapse on 1 or more days from baseline to participant’s follow-up to 90 days; or no relapse and no days with missing data on alcohol use from baseline to participant’s follow-up to 90 days.
d
Including only participants with confirmed relapse status; relapse on 1 or more days from baseline to participant’s final follow-up to a minimum of 159 days and a maximum of 180 days; or no relapse and no days with missing data on alcohol use from baseline to participant’s final follow-up to a minimum of 159 days and a maximum 180 days.
e
Adjusted for baseline alcohol consumption.
f
Adjusted for site and depression baseline score.
Secondary Outcomes
When comparing the ketamine plus therapy condition to the saline plus education condition, the results favored the former on percentage days abstinent (mean difference=15.9, 95% CI=3.8, 28.1) (see Table S1 in the online supplement), but there was no significant difference for odds of relapse (odds ratio=0.46, 95% CI=0.12, 1.74) (see Table 2). When comparing the ketamine plus therapy condition with the ketamine plus education condition, the results were not significant for percentage days abstinent (mean difference=4.2; 95% CI=−6.7, 15.2) (see Table S1) or odds of relapse (odds ratio=0.75, 95% CI=0.21, 2.65) (see Table 2). There were more days abstinent and lower odds of relapse in the ketamine plus therapy condition, but the confidence interval included the null (see Table 2 and Table S1).
The intention-to-treat analysis indicated a significant effect of ketamine compared with placebo for percentage days abstinent from alcohol at 3 months (mean difference=9.0, 95% CI=1.3, 16.7) (Figure 3; see also Table S2 in the online supplement). A significant reduction was found in BDI depressive symptoms in the ketamine compared with the placebo group at 3 months (mean difference=−2.6, 95% CI=−4.9, −0.4) (see Table 2). However, at 6 months no significant difference in mean BDI score between the ketamine and placebo conditions emerged (mean difference=−1.1, 95% CI=−3.7, 1.6) (see Table 2). On the HAM-D, differences in depressive symptoms at both 3 months and 6 months were nonsignificant (see Table 2).
Of the six Psychotomimetic States Inventory subscales, anhedonia showed a significant reduction at 3 months in the ketamine compared with the placebo group, with a 95% confidence interval that did not include the null effect (mean difference=−1.8, 95% CI=−3.1, −0.5), but not at 6 months (mean difference=−0.9, 95% CI=−2.4, 0.5) (see Table S4 in the online supplement). There were no differences in SF-12 mental and physical health subscale scores or in alcohol craving (see Table S4).
A correlation between percentage of self-reported drinking days in the timeline followback data (0.078%, SD=0.227) and percentage of SCRAM bracelet readings greater than 0 (mean=0.054%, SD=0.145) per participant between visits 2 and 8 was positive (r=0.75, p<0.001, 95% CI=0.63, 0.83) (see Figure S1 in the online supplement).
Adverse Events
Overall, 53 adverse events in 20 participants were rated by medical staff as either definitely (N=7), probably (N=3), or possibly (N=43) related to the study drug. None of these were rated as serious adverse events, and the majority were rated as mild. Four adverse events in three participants were rated as severe (i.e., significant symptoms that prevent normal daily activity), all in the active drug condition (low mood, hypertension, tachycardia, and euphoria). Two participants in the active drug condition withdrew because they could not tolerate the treatment. Six participants reported using ketamine on a single occasion during the follow-up period of the trial, and of these, three were allocated to the placebo group and three to the active drug treatment. All of these participants had used ketamine recreationally prior to participation in the trial.
Subjective Drug Effects
When asked whether they felt they had been given the study drug, 100% percent of patients in the ketamine group and 27% in the placebo condition reported that they had after the first infusion, 95% in the ketamine group and 34% in the placebo group after the second infusion, and 100% in the ketamine group and 23% in the placebo group after the third infusion. Subjective effects of dizziness, out-of-body experiences, altered reality perception, and altered time perception were not in the statistical analysis plan but are descriptively reported in the online supplement, showing a profile consistent with ketamine administration. Several indices of liver function indicated an improvement over the course of the trial. A LOESS fitted curve indicated a more linear improvement in participants in the ketamine group, whereas the placebo group showed a U-shaped response (see Figure S3 in the online supplement).
Blood Sample Analysis
Average ketamine blood levels, taken 2 hours after infusion, were similar across infusions 1, 2, and 3 (infusion 1: mean=60.3 ng/mL, SD=18.7; infusion 2: mean=66.5 ng/mL, SD=31.6; infusion 3: mean=66.1 ng/mL, SD=31.6) (see Figure S2 in the online supplement).
Exploratory Analysis Outcomes
The interaction between the drug and therapy conditions on days abstinent was not significant at 3- or 6-month follow-up (see Table S3 in the online supplement).
DISCUSSION
In this proof-of-concept study, we set out to examine the effect of ketamine alongside manualized mindfulness-based relapse prevention therapy on alcohol intake and relapse in currently abstinent patients with AUD over 6 months. The results showed that ketamine increased the number of days abstinent from alcohol at 3 and 6 months compared with placebo. The greatest difference in percentage of days abstinent from alcohol was between patients given ketamine and therapy and those given placebo and education. Overall relapse did not differ significantly between groups.
The longevity of the effect on percentage days abstinent was impressive, being maintained at 6 months following entry into the study after only three infusions. To our knowledge, this is the first phase 2 clinical trial to examine the therapeutic effects of ketamine in addiction over this long a follow-up period. The long-lasting nature of the therapeutic effect we saw here for alcohol use is consistent with other research in groups with AUD (12) but contrasts with studies in depression, where changes in symptoms are maintained for only around 2 weeks following infusion (29). The overall beneficial effect of alcohol abstinence and the participants’ adherence to the abstinence protocol were confirmed by the observation that liver function improved over the course of the trial. The impact of ketamine on alcohol abstinence was evident only for percentage days abstinent, not for relapse, which may be because binary outcome variables are less sensitive to detecting differences than more granular, continuous variables. Further, participants were required to have the goal of abstinence for at least the 6 months of the trial, but total abstinence was not a long-term goal in some cases, and this may have affected the findings. Nonetheless, the reductions in drinking and the concurrent improvements in liver function are clinically important, as these changes represent reductions in both mortality and morbidity in this often difficult-to-treat group.
To our knowledge, this is the first study in clinical research to include ketamine combined with psychological therapy alongside ketamine combined with a comparison “psychological” placebo. Alcohol education was used here as a therapy control, and it was associated with a smaller effect on drinking compared with the mindfulness-based relapse prevention therapy. While the sample size was small, these data suggest a possible beneficial effect of combining ketamine and psychological therapy that warrants further investigation. Whereas in the early work in AUD by Krupitsky and colleagues (13), ketamine was given alongside psychotherapy, in the contemporary research on treatment approaches in depression, ketamine has largely been given alone. Our findings and other emerging data (11) tentatively suggest that adding therapy may be a fruitful avenue for prolonging the clinical benefits of ketamine in both substance use disorders and depression. Recently Dakwar and colleagues combined ketamine with motivational enhancement therapy for AUD (12). Based on ketamine’s demonstrated positive effects on motivation to quit cocaine (30), combining these two interventions was expected to increase motivation to achieve and maintain alcohol abstinence. The Dakwar et al. study and the present study demonstrate mindfulness-based approaches to be effective in substance use disorders. Intuitively, this therapeutic approach is a good fit with ketamine, where the drug experience can act to bridge and bring added insights to early-stage mindfulness practice (31). The original work by Krupitsky et al. (13) used transpersonal therapy approaches incorporating elements of aversive therapy to facilitate aversion toward alcohol; this seemed to produce more pronounced effects, although the studies were conducted under very different conditions compared with more recent work. Participants were recruited from Russian alcohol and drug inpatient treatment settings. The dose and administration route in the present study also differed from those in the earlier research, where a single, higher dose of ketamine (2.5–3 mg/kg) was administered intramuscularly (13, 32); intramuscular administration was chosen in the earlier studies because of its longer-acting acute effects compared with intravenous administration. Concomitant medications were also given in the earlier studies (aethimizole, bemegride) to attempt to counter the amnestic effects of ketamine. The dose and administration route in the present study resemble those in Dakwar and colleagues’ recent randomized controlled trial for AUD (12), although in that study a single dose (0.7 mg/kg i.v.) was given to people meeting criteria for mild AUD who were currently drinking. The present study adds to the literature by demonstrating that repeated doses of ketamine are safe and efficacious in prolonging abstinence from alcohol in people with severe AUD who had stopped drinking prior to treatment. Dose-ranging studies have not been conducted, but it is important to establish the minimum effective dose, as ketamine treatment studies in AUD have generally opted for higher doses than those used in treatment-resistant depression. Future work should consider conducting dose-ranging studies.
An effect of ketamine on depressive symptoms at 3 months was found when assessed with the self-rated BDI, but not the clinician-rated HAM-D. Generally, the HAM-D is believed to place emphasis on somatic symptoms, whereas the BDI focuses on depressive cognitions (32, 33). It should also be noted that depression scores in this sample were on average low, likely as a result of the use of antidepressants being an exclusion criterion. Caution is therefore warranted for any interpretation of changes in depressive symptoms. One explanation for our findings might be that ketamine specifically affects anhedonia (34), as in this study we found anhedonia to be reduced at 3 months as assessed by the Psychotomimetic States Inventory anhedonia subscale, consistent with research in depression.
That ketamine can reduce both alcohol use and depression in AUD is encouraging therapeutically. While a clear link between depression and AUD is acknowledged, alcohol and mental health services still struggle to meet the needs of dual-diagnosis patients (35), so ketamine may represent a solution to this long-standing comorbidity. Identifying transdiagnostic factors common across depression and substance use disorders that may be common targets for ketamine—for example, alterations in reward sensitivity and anhedonia—will be important in advancing the use of ketamine in dual-diagnosis patients.
There were no serious adverse events associated with the trial drug, and adverse events were generally mild, suggesting that this treatment is well tolerated in this population. Ketamine in anesthesia is indicated for use with caution in people with AUD in the summary of product characteristics, although the results of this study suggest that at a subanesthetic dose, it is a well-tolerated treatment in this group, and that concurrent alcohol use problems need not be an exclusion criterion for ketamine treatment in other psychiatric settings, such as depression (36).
This study had a number of limitations, notably that the generalizability of the study findings is limited by the rigid enrollment criteria, such as the prohibition of antidepressant use. Furthermore, the blinding of both study conditions (psychotherapy and ketamine) was challenging, especially if participants had prior experience with either ketamine or psychological therapy. Saline was used instead of an active placebo, but studies reported since the start of our own study have demonstrated that midazolam does not have unintended treatment consequences and indeed is associated with reduced engagement with treatment in this patient group (12). The challenge of blinding to ketamine effects is a limitation of the study, and although it would not be entirely circumvented by use of midazolam as a control, particularly in a group of patients who are not naive to benzodiazepines or ketamine, it would certainly be reduced. Around one-third of patients in our placebo group believed they had been given the active drug, whereas nearly all the patients in the ketamine group thought they had been given the active drug, which could have an impact on their self-perceived efficacy in alcohol use. Therefore, future studies should use an active placebo to better maintain the blind. Given the functional unblinding component associated with ketamine, future studies should systematically ensure that all assessments are conducted by a person who has not observed any part of the drug treatment.
The inclusion in our sample of some individuals who had prior experience of ketamine may have compounded functional unblinding issues. Individuals with more positive expectations of ketamine based on previous experiences may have been more likely to volunteer to take part in the trial, although the majority of participants (73%) reported no previous ketamine use. While including this group may be seen as a weakness of the study, the absence of subsequent problematic ketamine use suggests that this therapy may be suitable for those with such experimental recreational ketamine experiences. Ketamine use rates are high in the United Kingdom, where the study was conducted, with lifetime rates at 1.9% (37). Because rates will likely be still higher in a group with AUD, particularly among 16- to 24-year-olds (37), excluding individuals with any prior ketamine experience may become increasingly problematic if this is to be a widely adopted treatment.
Nearly half of our sample reported experimental use of psilocybin or LSD; individuals’ previous experiences with other psychedelic substances may have influenced expectations from ketamine treatment.
A formal assessment of the effect of therapeutic alliance would be a further important addition to future studies. The use of the Mystical Experience Questionnaire was not considered at the time we designed the study as this did not relate to our hypotheses, and we made the decision not to use the Clinician-Administered Dissociative States Scale in order to keep to a minimum the measures that participants were completing under the influence of ketamine. In retrospect, however, it would have been helpful to include these, and they would be an important addition to future studies. Given heterogeneity in baseline alcohol use, future studies might consider using individualized markers of drinking, such as total number of drinks consumed or multiple event approaches such as number of days of heavy drinking. Lastly, a dose-finding study might be an important avenue for future research, given the absence of such a study in AUD.
In summary, this trial demonstrated that three subanesthetic infusions of ketamine supported abstinence from alcohol and that abstinence may possibly be further enhanced when ketamine treatment is combined with therapy. Overall, the treatment was well tolerated. The data presented here, along with emerging data from other studies of ketamine in AUD, suggest that a further definitive trial is warranted.
Footnotes
Dr. David Gilhooly died in May 2019.
ClinicalTrials.gov identifier: NCT02649231.
The authors thank Dr. Evgeny Krupitsky, pioneering researcher on ketamine as a treatment, for his input into the design of the study.
Supplementary Material
File (appi.ajp.2021.21030277.ds001.pdf)
- View/Download
- 477.49 KB
References
1.
World Health Organization: Global Status Report on Alcohol and Health 2018. Geneva, World Health Organization, 2018
2.
Anton RF, O’Malley SS, Ciraulo DA, et al: Combined Pharmacotherapies and Behavioral Interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295:2003–2017
3.
Zarate CA Jr, Singh JB, Carlson PJ, et al: A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63:856–864
4.
Greenfield SF, Weiss RD, Muenz LR, et al: The effect of depression on return to drinking: a prospective study. Arch Gen Psychiatry 1998; 55:259–265
5.
Brière FN, Rohde P, Seeley JR, et al: Comorbidity between major depression and alcohol use disorder from adolescence to adulthood. Compr Psychiatry 2014; 55:526–533
6.
Chambers RA: Adult hippocampal neurogenesis in the pathogenesis of addiction and dual diagnosis disorders. Drug Alcohol Depend 2013; 130:1–12
7.
Mandyam CD, Koob GF: The addicted brain craves new neurons: putative role for adult-born progenitors in promoting recovery. Trends Neurosci 2012; 35:250–260
8.
Bates ME, Buckman JF, Nguyen TT: A role for cognitive rehabilitation in increasing the effectiveness of treatment for alcohol use disorders. Neuropsychol Rev 2013; 23:27–47
9.
Birch AM, McGarry NB, Kelly ÁM: Short-term environmental enrichment, in the absence of exercise, improves memory, and increases NGF concentration, early neuronal survival, and synaptogenesis in the dentate gyrus in a time-dependent manner. Hippocampus 2013; 23:437–450
10.
Ivan Ezquerra-Romano I, Lawn W, Krupitsky E, et al: Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacology 2018; 142:72–82
11.
Wilkinson ST, Rhee TG, Joormann J, et al: Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: a randomized clinical trial. Psychother Psychosom 2021; 90:318–327
12.
Dakwar E, Levin F, Hart CL, et al: A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry 2020; 177:125–133
13.
Krupitsky EM, Grinenko AY: Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drugs 1997; 29:165–183
14.
Das RK, Gale G, Walsh K, et al: Ketamine can reduce harmful drinking by pharmacologically rewriting drinking memories. Nat Commun 2019; 10:5187
15.
McAndrew A, Lawn W, Stevens T, et al: A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial. Trials 2017; 18:159
16.
Chawla N, Collin S, Bowen S, et al: The Mindfulness-Based Relapse Prevention Adherence and Competence Scale: development, interrater reliability, and validity. Psychother Res 2010; 20:388–397
17.
Petrakis IL, Limoncelli D, Gueorguieva R, et al: Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry 2004; 161:1776–1782
18.
Lejoyeux M, Solomon J, Adès J: Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol 1998; 33:563–575
19.
Mollaahmetoglu OM, Keeler J, Ashbullby KJ, et al: “This is something that changed my life”: a qualitative study of patients’ experiences in a clinical trial of ketamine treatment for alcohol use disorder. Front Psychiatry 2021; 12:695335
20.
Garbutt JC, Kampov-Polevoy AB, Gallop R, et al: Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 2010; 34:1849–1857
21.
Beck A, Steer R, Brown G: BDI-II, Beck Depression Inventory: Manual. San Antonio, Tex, Psychological Corp, 1996
22.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56–62
23.
Ware J Jr, Kosinski M, Keller SDA: A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34:220–233
24.
Mason OJ, Morgan CJ, Stefanovic A, et al: The Psychotomimetic States Inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis. Schizophr Res 2008; 103:138–142
25.
Heatherton TF, Kozlowski LT, Frecker RC, et al: The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86:1119–1127
26.
Singleton EG, Tiffany ST, Henningfield JE: Development and validation of a new questionnaire to assess craving for alcohol. Probl Drug Depend 1994; 1995:289
27.
Morgan CJ, Rossell SL, Pepper F, et al: Semantic priming after ketamine acutely in healthy volunteers and following chronic self-administration in substance users. Biol Psychiatry 2006; 59:265–272
28.
Sedgwick P, Marston L: Meta-analyses: standardised mean differences. BMJ 2013; 347:f7257
29.
Murrough JW, Perez AM, Pillemer S, et al: Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2013; 74:250–256
30.
Dakwar E, Levin F, Foltin RW, et al: The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. Biol Psychiatry 2014; 76:40–46
31.
Dakwar E, Nunes EV, Hart CL, et al: A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry 2019; 176:923–930
32.
Brown C, Schulberg HC, Madonia MJ: Assessment depression in primary care practice with the Beck Depression Inventory and the Hamilton Rating Scale for Depression. Psychol Assess 1995; 7:59–65
33.
Schneibel R, Brakemeier E-L, Wilbertz G, et al: Sensitivity to detect change and the correlation of clinical factors with the Hamilton Depression Rating Scale and the Beck Depression Inventory in depressed inpatients. Psychiatry Res 2012; 198:62–67
34.
Lally N, Nugent AC, Luckenbaugh DA, et al: Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry 2014; 4:e469
35.
Institute of Alcohol Studies; Centre for Mental Health: Alcohol and Mental Health: Policy and Practice in England (Factsheet Series). London, Institute of Alcohol Studies and Centre for Mental Health, April 2018
36.
Electronic Medicines Compendium: Ketamine 50 mg/mL Injection. https://www.medicines. org.uk/emc/product/6935/
37.
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): European Drug Report 2020: Trends and Developments. Luxembourg, Publications Office of the European Union, 2020 (https://www.emcdda.europa.eu/publications/ edr/trends-developments/2020_en)
Information & Authors
Information
Published In
History
Received: 14 March 2021
Revision received: 18 June 2021
Revision received: 8 August 2021
Revision received: 28 September 2021
Accepted: 4 October 2021
Published online: 11 January 2022
Published in print: February 2022
Keywords
Authors
Author Contributions
Drs. Grabski and McAndrew are co-first authors.
Competing Interests
Drs. Grabski, McAndrew, Lawn, Marsh, Hill, Harris, and Morgan have received royalties for KARE therapy license distribution; KARE therapy is licensed from University of Exeter to Awakn Life Sciences. Ms. Mollaahmetoglu has conducted research work funded by Awakn Life Sciences. Dr. Bloomfield owns shares in Bloomfield Health Holdings Limited. Prof. Curran has served as a consultant for Janssen Research and Development. Prof. Lingford-Hughes has received Ph.D. funding from Alcarelle and an honorarium from Lundbeck for an educational talk and has served as a consultant for Silence Therapeutics. Prof. Morgan has received research funding from Awakn Life Sciences and has served as a consultant for Janssen Pharmaceuticals. The other authors report no financial relationships with commercial interests.
Funding Information
Supported by Medical Research Council grant L-023032 to Dr. Morgan, Dr. Lingford-Hughes, and Dr. Curran.
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).